Barclays PLC Purchases 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Barclays PLC grew its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 105.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 94,915 shares of the company’s stock after purchasing an additional 48,614 shares during the period. Barclays PLC owned about 0.17% of Olema Pharmaceuticals worth $1,133,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OLMA. Ensign Peak Advisors Inc increased its holdings in shares of Olema Pharmaceuticals by 6.1% in the second quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after buying an additional 850 shares during the period. EP Wealth Advisors LLC increased its stake in Olema Pharmaceuticals by 5.2% in the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after purchasing an additional 2,407 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Olema Pharmaceuticals by 67.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock worth $132,000 after purchasing an additional 4,442 shares during the period. The Manufacturers Life Insurance Company lifted its position in Olema Pharmaceuticals by 52.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,888 shares of the company’s stock valued at $172,000 after purchasing an additional 5,449 shares during the last quarter. Finally, Conway Capital Management Inc. purchased a new stake in shares of Olema Pharmaceuticals during the third quarter valued at approximately $119,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 8,256 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $77,358.72. Following the sale, the director now directly owns 772,277 shares of the company’s stock, valued at approximately $7,236,235.49. The trade was a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The shares were bought at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the acquisition, the insider now directly owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 773,797 shares of company stock worth $5,414,609. 19.40% of the stock is currently owned by company insiders.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $4.84 on Tuesday. Olema Pharmaceuticals, Inc. has a 1 year low of $4.60 and a 1 year high of $16.77. The firm has a market cap of $277.32 million, a price-to-earnings ratio of -2.21 and a beta of 2.05. The company has a 50-day moving average of $8.20 and a 200 day moving average of $10.96.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.